Axsome Therapeutics (AXSM) Q1 2024: Avelity Prescriptions Jump 206% as Coverage Expands, Pipeline Milestones Stack Up

May 6, 2024 | By EarningsIQ Research

Avelity, Axsome’s lead depression therapy, delivered triple-digit prescription growth and expanded payer access, while the company advanced multiple late-stage neuroscience programs. Commercial execution is driving earlier-line adoption, but higher operating expenses and pipeline investments are stretching cash burn. Investors should watch for pivotal trial readouts and further coverage wins to shape the next phase of growth.

Summary

• Commercial Acceleration: Avelity prescriptions surged as salesforce and payer contracting efforts deepened market penetration.
• Pipeline Momentum: Multiple late-stage trials advanced, targeting new indications in high-need CNS disorders.
• Coverage Expansion: New GPO contracts set the stage for broader access and volume gains in coming quarters.

Business Overview

Axsome Therapeutics develops and commercializes therapies for central nervous system (CNS) disorders, with a focus on major depressive disorder (MDD), narcolepsy, and sleep apnea. The company’s revenue is primarily derived from sales of Avelity, a novel oral antidepressant, and Sunosi, a wake-promoting agent for narcolepsy and sleep apnea. Axsome’s model combines branded pharmaceutical sales with a late-stage pipeline spanning depression, Alzheimer’s agitation, migraine, fibromyalgia, and binge eating disorder.

Performance Analysis

The first quarter showcased robust commercial execution, with Avelity net product sales up 240% year-over-year and total prescriptions reaching approximately 95,000, reflecting both new patient starts and growing prescriber adoption. Sunosi also posted double-digit prescription growth versus the prior year, though it saw a modest sequential decline in line with expected seasonality in the excessive daytime sleepiness market.

Operating expenses rose sharply, with R&D and SG&A up due to expanded clinical activity and a larger sales force, driving a higher net loss. Gross-to-net discounts remained in the mid-50% range for both lead products, consistent with industry norms but indicative of ongoing payer dynamics. Cash burn was notable, but management stated that the $331 million cash balance is sufficient to reach cash flow positivity under the current plan.

• Prescription Surge: Avelity’s 206% YoY prescription growth outpaced branded competitors, underlining strong demand and effective commercial expansion.
• Coverage Stability: Avelity maintained ~70% payer coverage, with Sunosi at 83%, and new GPO contracts are expected to drive further gains.
• Expense Scaling: R&D and SG&A increases reflect late-stage pipeline activity and commercial scaling, with non-cash stock comp a significant component.

Despite seasonality and a brief cyberattack disruption, underlying demand trends rebounded quickly, and the sales team’s expansion is already driving higher new patient starts and earlier-line use.

Executive Commentary

Strategic Positioning

1. Deepening Avelity Market Penetration

Salesforce expansion and digital campaigns are fueling broader prescriber activation and earlier-line adoption, with 50% of prescriptions now first or second line. New GPO contracts are expected to further accelerate access and volume, especially as PBMs implement favorable formulary decisions. This positions Avelity as a go-to MDD therapy in both psychiatry and primary care.

2. Pipeline Value Creation

Axsome’s late-stage pipeline is advancing across multiple CNS indications, including pivotal trials for AXS-12 (narcolepsy), AXS-05 (Alzheimer’s agitation), AXS-07 (migraine), and AXS-14 (fibromyalgia). Positive readouts and regulatory submissions are expected throughout 2024 and 2025, with each candidate targeting large, underserved patient populations.

3. Managed Care and Access Strategy

Payer contracting is a central strategic lever, with Axsome now contracted with two of the three largest GPOs for Avelity. The company is focused on pulling through these agreements with underlying PBMs to meaningfully expand covered lives, which should drive incremental volume and stabilize gross-to-net dynamics.

4. Commercial Model Scalability

Management is actively evaluating sales force sizing and structure, especially as new indications like fibromyalgia approach launch. The overlap between CNS comorbidities supports efficient cross-promotion, but future launches will require careful resource allocation to balance growth and profitability.

Key Considerations

This quarter marks a critical inflection for Axsome’s commercial and pipeline trajectory. Execution on coverage, prescriber activation, and clinical milestones will determine the company’s ability to scale profitably and capture share in large CNS markets.

Key Considerations:

• Coverage Expansion Catalysts: Pull-through on new GPO contracts could drive a step-change in Avelity volume and earlier-line adoption.
• Pipeline Readout Timing: Multiple late-stage trials will read out in the next 12-18 months, providing catalysts and risk points for the stock.
• Expense Discipline: R&D and SG&A growth must be balanced with revenue scaling to avoid prolonged cash burn as the portfolio broadens.
• Market Access Leverage: Negotiations with the remaining major GPO and PBMs are ongoing, with incremental coverage seen as a key growth unlock.

Risks

Axsome faces execution risk on both commercial and pipeline fronts. Payer negotiations are complex, and delays in PBM pull-through could slow access expansion. Pipeline readouts carry binary risk, and increased R&D spending could pressure cash if timelines slip. The evolving competitive landscape in CNS therapeutics, especially with new entrants and generics, remains a persistent threat. Regulatory outcomes and payer coverage decisions will be critical determinants of future performance.

Forward Outlook

For Q2 2024, Axsome expects:

• Continued growth in Avelity and Sunosi prescriptions as coverage expands and salesforce productivity ramps.
• Submission of the AXS-07 NDA for migraine and AXS-14 NDA for fibromyalgia.

For full-year 2024, management maintained its guidance:

• Cash runway sufficient to reach cash flow positivity under the current plan.

Management highlighted several factors that will shape results:

• Timing and magnitude of PBM adoption under new GPO contracts.
• Late-stage pipeline trial completions and regulatory submissions.

Takeaways

Axsome’s commercial execution is translating into rapid prescription growth and earlier-line use, while the pipeline is positioned to deliver multiple pivotal readouts in the next year. Coverage expansion remains the biggest commercial lever, and expense scaling must be watched as the pipeline matures.

• Growth Engine: Avelity’s accelerating adoption and expanded payer access are driving revenue and market share gains in MDD, with Sunosi providing a secondary growth pillar.
• Pipeline Leverage: Upcoming trial results in narcolepsy, Alzheimer’s agitation, migraine, and fibromyalgia offer meaningful upside but also introduce execution and regulatory risk.
• Coverage and Cost Discipline: Investors should watch for further coverage wins and signs of operating leverage as Axsome manages growth and profitability trade-offs.

Conclusion

Axsome enters the balance of 2024 with strong commercial momentum and a pipeline stacked with high-impact readouts. The next quarters will test the company’s ability to convert coverage wins and pipeline milestones into sustainable, profitable growth in the competitive CNS therapeutics market.

Industry Read-Through

Axsome’s results reinforce several key trends in CNS therapeutics: Rapid adoption of differentiated antidepressants is possible with strong payer access and prescriber activation, while gross-to-net pressures remain a persistent headwind. The company’s focus on earlier-line use and digital engagement reflects a broader shift toward primary care-driven CNS prescribing. Pipeline advancement in high-need indications like Alzheimer’s agitation and narcolepsy signals continued innovation and commercial opportunity, but also highlights the capital intensity and execution risk inherent in CNS drug development. Other CNS players should note the importance of access contracting and the potential for digital-first commercial models to accelerate adoption in complex markets.

AXSM Healthcare Pharmaceuticals CNS Commercialization Pipeline Coverage Neuroscience